Kiromic
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7707 Fannin St Ste 140, Houston, Texas, ...Phone Number
(832) 968-4888Website
www.kiromic.comRevenue
<$5 MillionStock Symbol
KRBPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Kiromic
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) platform to discover, validate and develop celland gene therapies with a therapeutic focus on immuno-oncology. Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. Kiromic's DIAMOND AI is where data science meets target identification to dramatically compress the years and millions of dollars required to develop a cellular therapeutic. The Company maintains offices in Houston, Texas.Explore more
Popular SearchesKiromicKiromic BiopharmaKiromic Biopharma IncKiromic LLCKiromic IncSIC Code 87,873NAICS Code 54,541Ticker OTC: KRBPShow more
Kiromic Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kiromic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Kiromic had a recent Job posting/layoffs
Check if Kiromic has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Kiromic has new funding data
Congratulate Masked Content for being promoted to Masked Content at Kiromic
Kiromic, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Kiromic is spiking on competitors!
Product Launch: Get notified when Kiromic launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Kiromic recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Kiromic as Masked Content
Find more new buyers
Compare Similar Companies to Kiromic
Compare insights from companies similar to Kiromic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kiromic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kiromic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kiromic.
Kiromic financials insights
Gather financial insights about Kiromic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$15M
Kiromic Tech Stack
A closer look at the technologies used by Kiromic
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Project
Product Development, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Product Development
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Kiromic
Sign Up For FreeTo access detailed company insights
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) platform to discover, validate and develop celland gene therapies with a therapeutic focus on immuno-oncology. Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell thera... Read More
